New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

James Kihara Biography and Net Worth

Insider of ACADIA Pharmaceuticals

James Kihara serves as Principal Accounting Officer of the Company. He has been with the Company since March 2020. Prior to joining the Company, Mr. Kihara worked at Cubic Corporation, an information technology and services firm, from November 2012 to March 2020, most recently serving as chief financial officer of the Cubic Mission Solutions business segment. Prior to Cubic Corporation, Mr. Kihara was employed by Ernst & Young LLP, a multinational professional services firm, and served as a Senior Manager of Assurance Services. Mr. Kihara earned a bachelor’s degree in Business Administration (Accounting) from San Diego State University and is a certified public accountant in the State of California.

What is James Kihara's net worth?: The estimated net worth of James Kihara is at least $323,171.01 as of November 19th, 2024. Mr. Kihara owns 19,863 shares of ACADIA Pharmaceuticals stock worth more than $323,171 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Kihara may own. Learn More about James Kihara's net worth.
How old is James Kihara?: Mr. Kihara is currently 43 years old. There are 5 older executives and no younger executives at ACADIA Pharmaceuticals. The oldest executive at ACADIA Pharmaceuticals is Mr. Stephen R. Davis J.D., President, CEO & Director, who is 63 years old. Learn More on James Kihara's age.
How do I contact James Kihara?: The corporate mailing address for Mr. Kihara and other ACADIA Pharmaceuticals executives is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. ACADIA Pharmaceuticals can also be reached via phone at (858) 558-2871 and via email at [email protected]. Learn More on James Kihara's contact information.
Has James Kihara been buying or selling shares of ACADIA Pharmaceuticals?: Within the last three months, James Kihara has sold $68,467.13 of ACADIA Pharmaceuticals stock. Most recently, James Kihara sold 4,073 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a transaction totalling $68,467.13. Following the completion of the sale, the insider now directly owns 19,863 shares of the company's stock, valued at $333,897.03. Learn More on James Kihara's trading history.
Who are ACADIA Pharmaceuticals' active insiders?: ACADIA Pharmaceuticals' insider roster includes Laura Brege (Director), Stephen Davis (CEO), James Kihara (Insider), Austin Kim (EVP), Elena Ridloff (CFO), Mark Schneyer (CFO), Srdjan Stankovic (President), and Brendan Teehan (COO). Learn More on ACADIA Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ACADIA Pharmaceuticals?: During the last year, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 172,819 shares worth more than $3,042,092.93. The most recent insider tranaction occured on November, 19th when COO Brendan Teehan sold 10,329 shares worth more than $173,630.49. Insiders at ACADIA Pharmaceuticals own 28.3% of the company. Learn More about insider trades at ACADIA Pharmaceuticals.
Information on this page was last updated on 11/19/2024.

James Kihara Insider Trading History at ACADIA Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2024	Sell	4,073	$16.81	$68,467.13	19,863
5/2/2024	Sell	1,326	$16.94	$22,462.44	14,370
4/8/2024	Sell	1,790	$17.87	$31,987.30	13,100
2/26/2024	Sell	474	$24.67	$11,693.58	11,391
12/15/2023	Sell	2,000	$28.30	$56,600.00	11,025
11/20/2023	Sell	1,985	$22.64	$44,940.40	13,025
9/15/2023	Sell	2,000	$25.88	$51,760.00	10,778
6/15/2023	Sell	2,000	$24.15	$48,300.00	9,144
5/17/2023	Sell	5,947	$22.50	$133,807.50	11,144
4/10/2023	Sell	523	$18.14	$9,487.22	5,197
4/6/2023	Sell	701	$18.16	$12,730.16	4,231
2/24/2023	Sell	350	$18.78	$6,573.00	2,923
4/8/2022	Sell	1,025	$27.05	$27,726.25	2,433
2/23/2022	Sell	359	$23.80	$8,544.20

James Kihara Buying and Selling Activity at ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $16.27

$16.05

$16.39

50 Day Range

MA: $15.61

$14.29

$18.27

2 Week Range

Now: $16.27

$14.15

$32.59

Volume

1,087,297 shs

Average Volume

1,679,200 shs

Market Capitalization

$2.71 billion

P/E Ratio

20.86

Dividend Yield

N/A

Beta

0.38

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

From Darwin | Ad